药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Labetuzumab govitecan
The risk or severity of adverse effects can be increased when Labetuzumab govitecan is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Vanucizumab
The risk or severity of adverse effects can be increased when Vanucizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
GS-5745
The risk or severity of adverse effects can be increased when GS-5745 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Luspatercept
The risk or severity of adverse effects can be increased when Luspatercept is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Aducanumab
The risk or severity of adverse effects can be increased when Aducanumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ascrinvacumab
The risk or severity of adverse effects can be increased when Ascrinvacumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Cixutumumab
The risk or severity of adverse effects can be increased when Cixutumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Inclacumab
The risk or severity of adverse effects can be increased when Inclacumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Etaracizumab
The risk or severity of adverse effects can be increased when Etaracizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ganitumab
The risk or severity of adverse effects can be increased when Ganitumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Zalutumumab
The risk or severity of adverse effects can be increased when Zalutumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Etrolizumab
The risk or severity of adverse effects can be increased when Etrolizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tralokinumab
The risk or severity of adverse effects can be increased when Tralokinumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Dupilumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Fasinumab
The risk or severity of adverse effects can be increased when Fasinumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Simtuzumab
The risk or severity of adverse effects can be increased when Simtuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Duligotuzumab
The risk or severity of adverse effects can be increased when Duligotuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Gevokizumab
The risk or severity of adverse effects can be increased when Gevokizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Sotatercept
The risk or severity of adverse effects can be increased when Sotatercept is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tarextumab
The risk or severity of adverse effects can be increased when Tarextumab is combined with Belantamab mafodotin.